Posts

Showing posts with the label ipo subscription

Shreenath Paper Products IPO listing today. Here's what GMP signals ahead of debut

Image
[hfe_template id='11223'] [ad_1] Shreenath Paper Products saw a subdued response for its IPO and the company's shares will debut on the BSE SME platform on Wednesday. Ahead of the listing, the GMP is Nil in the grey market. Most of the SME IPOs this year had zero premiums in the unofficial market, impacted by the correction in the equities. The company offered around 53 lakh shares to investors, where the IPO was subscribed just over 1.5x. Retail investors made the highest bids, which was not backed up by non-institutional investors. Shreenath Paper will use the Rs 23 crore it raised from the IPO for meeting incremental working capital requirements and general corporate purposes. Shreenath Paper Products: Company overview The company is a leading supply chain solutions provider, catering to industries where paper forms a major part of raw materials. It specialises in supplying a wide range of paper products, including sublimation base paper, thermal base paper, straw...

Unimech Aerospace and Manufacturing shares drop over 9% post listing

Image
[hfe_template id='11223'] [ad_1] Shares of Unimech Aerospace and Manufacturing fell 9.4% to Rs 1,350.4 on the BSE after their strong debut on the exchanges on Tuesday. The stock debuted at Rs 1,491 on the BSE, with a premium of Rs 706 or 90% over the IPO price of Rs 785. On NSE, the shares debuted at Rs 1,460. The Rs 500-crore IPO of high-precision engineering solutions provider Unimech Aerospace, comprising a fresh issue of Rs 250 crore and an offer-for-sale of Rs 250 crore, was open for subscription during December 23-26. The company’s IPO received an overall subscription of 175.31 times as it attracted bids for 82.46 crore equity shares against 47.04 lakh shares on the offer. The retail investors portion was subscribed 56.74 times, while the non institutional investors subscribed by 263.78 times. Meanwhile, the qualified institutional buyers category was booked 317.63 times. Also Read :Sensex & Nifty in 2025: Predictions, targets, must-have stocks for the new year...

Dhanlaxmi Crop Science IPO: Shares to debut today. Here's what GMP indicates

Image
[hfe_template id='11223'] [ad_1] The shares of Dhanlaxmi Crop Science will debut on the NSE SME platform on Monday. Ahead of the listing, the company's shares were trading with a GMP of Rs 50 in the grey market. Considering the upper price band of Rs 55, the stock is expected to list with maximum gains of 90% over issue price. However, it is important to note that grey market premiums are just an indicator as to how the company's shares are stacked up in the unlisted market and are subject to change rapidly. The net proceeds from the public offer will be used for working capital requirements, issue expenses and general corporate purposes. The IPO, which was completely a fresh equity sale of 43.28 lakh shares, received overwhelming response from investors with a subscription of 550 times at close. Dhanlaxmi Crop Science is a technology driven seeds company that develops, produces, processes and sells seeds for a range of field crops and vegetables, have more than ...

Nephro Care IPO opens today: Check issue size, price band, GMP and other details

Image
[hfe_template id='11223'] [ad_1] The SME IPO of Nephro Care opened for subscription earlier today and will close on July 2. The company aims to raise about Rs 41.26 crore through the SME IPO and list the shares on NSE SME platform. Here are 10 key things investors need to know about the public offer before subscribing to the issue. 1) About Nephro Care Nephro Care is a one stop treatment centre based in Kolkata that offers a wide range of clinical and lifestyle solutions and services and renal insufficiency treatment to patients. The treatment framework covers the entire range of lifestyle, physiological and spiritual aspects of wellness. 2) Industry overview CKD is a severe public health issue in India. As per government estimates, nearly 2,20,000 patients develop end-stage renal disease (ESRD) annually in India, leading to an additional annual dialysis demand of 34 million treatment sessions. Unfortunately, in India, renal insufficiency treatment focuses more on curati...